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Introduction {#sec1}
============

*Aspergillus fumigatus* is an opportunistic, potentially life-threatening fungus, which thrives mainly on organic substrates like decaying vegetation in the soil or food. Although environmental exposure of humans to the airborne *A. fumigatus* conidia is common, host-pathogen interactions effectively eradicate conidia from the pulmonary region of healthy individuals ([@bib29], [@bib31]). The key determinant of infection is thought to be the innate immune response. *A. fumigatus* conidia in the alveolar space of lungs trigger pathogen recognizing receptors (PRRs), driving the first responders of the immune system ([@bib7]). Key cellular mediators of immunity include resident alveolar macrophages, monocytes and dendritic cells for the engulfment of conidia, and neutrophils for the destruction of hyphae using neutrophil extracellular traps ([@bib24], [@bib35], [@bib39], [@bib56]).

Healthy individuals effectively clear *A. fumigatus*, whereas infection becomes life-threatening in immunocompromised patients. With an increasing number of immunocompromised patients from organ transplantation or cancer treatment, invasive pulmonary aspergillosis (IPA) is rapidly growing as a medical problem ([@bib4]). The acute inflammation in the lungs of patients with IPA suggests an underlying malfunction, rather than absence, of essential host immune components as the causative factor ([@bib25]). The *modus operandi* for the clinical use of immunosuppressive drugs mainly includes cyclophosphamide (CY) ([@bib11]) and hydrocortisone acetate (HCA) ([@bib14], [@bib41]) administered intravenously to the patients. In previous studies, it was shown that the pathophysiology of IPA and the immune response against the fungal infection differs for each compounds ([@bib7], [@bib45]). Corticosteroids treatment impairs phagocyte function, including an abnormality in cellular migration and production of the inflammatory cytokines, while leaving neutrophils intact and functional ([@bib6], [@bib22], [@bib32]). The phagocytic defect permits infection growth, which in turn drives a massive recruitment of neutrophils to the site of infection, resulting in intensive tissue damage. By contrast, CY induces neutropenia and depletes other circulating white blood cells, while leaving the local innate immune response relatively intact. Here the neutropenia is thought to be critical in permitting hyphal growth and further invasion in the tissue ([@bib20], [@bib21]). A key limitation of these conclusions, however, is the reliance on invasive methods that are restricted to single time point measurements, such as immunohistochemistry ([@bib3], [@bib52]). Knowledge of immune kinetics and longitudinal disease progression is currently lacking but is essential for understanding the dynamics of these processes ([@bib21]). *In vivo* imaging techniques are potentially able to assess the host response against the infection longitudinally in individual animals.

Different imaging techniques have been used in preclinical models to characterize IPA, such as computed tomography, positron emission tomography, bioluminescence imaging, single photon emission tomography, proton magnetic resonance imaging (^1^H MRI), and fibered confocal fluorescence microscopy ([@bib5], [@bib33], [@bib34], [@bib36], [@bib50], [@bib53]). Although these approaches fulfill the non-invasive and longitudinal criteria required, they lack specific information on inflammatory processes occurring in the host. In other disease models, *ex vivo* and *in vivo* cell labeling approaches use ^1^H MRI contrast agents to visualize immune cells for studying various inflammatory processes ([@bib8], [@bib16], [@bib40], [@bib55]). However, ^1^H MRI contrast agents such as (super)paramagnetic nanoparticles generate unspecific signal voids, making it difficult to locate and quantify labeled cells *in vivo*. Fluorine contrast agents in combination with ^19^F MRI may provide an alternative, with specific and quantifiable contrast ([@bib10], [@bib43], [@bib57]).

^19^F MRI is an emerging non-invasive tool, which can be applied both for imaging of *ex vivo* contrast agent labeled cells after their transplantation and for *in vivo* labeling of cells after systemic administration of fluorinated contrast agents ([@bib18], [@bib42], [@bib44]). Using fluorinated contrast agents such as perfluoro-15-crown-5-ether nanoparticles (PFCE-NPs) in combination with ^19^F MRI, one can generate highly specific MR contrast, owing to the lack of background signal. Overlaying the ^19^F MR image with a conventional ^1^H MR image provides the necessary anatomical background ([@bib27]).

Here, we developed an imaging platform allowing non-invasive and longitudinal quantification of the degree of pulmonary inflammation in IPA murine models. We showed that the *in vivo* labeling of immune cells with newly developed zonyl perfluoro-15-crown-5-ether nanoparticles (ZPFCE-NPs) reveal underlying pathophysiological events during acute IPA using ^19^F MRI.

Results {#sec2}
=======

Small-Sized Biocompatible ZPFCE-NPs Showed Efficient *In Vitro* Labeling of Murine Phagocytes {#sec2.1}
---------------------------------------------------------------------------------------------

To monitor the immune responses *in vivo*, we sought to exploit the functional property of phagocytosis for immune cells labeling. ZPFCE-NPs label professional phagocytic cells owing to their small size ([@bib51]). To validate the feasibility of this strategy, Macrophages, identified by their characteristic high surface expression of CD11b and F4/80, successfully phagocytosed ZPFCE-NPs in a dose-dependent manner ([Figure 1](#fig1){ref-type="fig"}). ZPFCE-NP labeling of macrophages showed similar labeling efficiencies for particle concentrations of 1 and 10 mM ([Figure 1](#fig1){ref-type="fig"}A). We used ZPFCE-NPs incorporated with Cholesteryl BODIPY FLC 12 green fluorescent dye. These nanoparticles did not show nanotoxicity in primary macrophages upon labeling with relatively high concentrations, affirming their suitability for *in vivo* applications ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1ZPFCE-NPs Allow Labeling of Macrophages(A) Labeling of macrophages (positive cells for F4/80 and CD11b surface marker) with ZPFCE-NPs was measured in terms of percentage uptake at variable doses of particles. Median fluorescence intensities were measured from the gated ZPFCE-NP-labeled macrophages for each dose (mean ± SD).(B) Confocal image showing macrophages stained by F4/80 surface (red) with the ZPFCE-NPs (green), magnified representative images show intracellular uptake of ZPFCE-NPs. Scale bar is 20μm.

A key requirement for an *in vivo* labeling protocol is that the label does not interfere with the biological processes being measured. To investigate whether ZPFCE-NP labeling modulates macrophage function, we tested key innate and adaptive functions *in vitro*. Using cytokine secretion as a readout for innate functional activation of macrophages, we found no impact of ZPFCE-NPs on spontaneous or lipopolysaccharide (LPS)-induced immune activation at a dose of 1 mM and only a weak enhancement of LPS-induced TNF-alpha production at 10 mM ([Figure 2](#fig2){ref-type="fig"}A). For the adaptive immune system, we tested the biological effect of ZPFCE-NPs labeling on antigen-presentation by macrophages. C57BL/6 peritoneal macrophages were pre-labeled with ZPFCE-NPs and pulsed with OVA peptide (OVA323-339) before co-culture with OVA-reactive OT-II TCR transgenic CD4+ T cells. OT-II T cells showed efficient activation when primed with OVA-loaded macrophages, which was unaltered by the pre-loading with ZPFCE-NPs ([Figure 2](#fig2){ref-type="fig"}B). Together, these results demonstrate that 1 mM ZPFCE-NPs allow macrophage labeling without inducing biological alterations to either the innate or adaptive functions of macrophages.Figure 2ZPFCE-NPs Allow Labeling of Murine Macrophages without Modulating Their Innate and Adaptive Immune Function(A) Cytokine measurements performed on supernatants from ZPFCE-labeled macrophages in the presence and absence of LPS. Data represent mean ± SEM (*n* = 5, \*\*\*\*p \< 0.0001).(B) C57BL/6 peritoneal macrophages were pre-loaded with ZPFCE-NPs and pulsed with OVA peptide (OVA~323-339~) at different concentrations, before co-culture with OT-II TCR transgenic CD4+ T cells. After 3 days of co-culture, the cells were stained for lineage T cell markers in combination with T cell activation markers and analyzed by flow cytometry. The percentage of CD44^high^CD62L^low^ activated T cells across variable doses of the OT-II peptide, for ZPFCE-NP-labeled and unlabeled macrophages (mean ± SEM).

^19^F MRI Allows *In Vivo* Visualization and Quantification of Immune Cell Recruitment in *A. fumigatus*-Infected Lungs {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------

Having validated ZPFCE-NPs as an efficient and biologically neutral contrast agent for macrophages, we sought to assess the *in vivo* utility using IPA mouse models to apply our methodology as a proof of principle. To test the robustness of our immunomonitoring method, we used three models of pulmonary aspergillosis with immunocompetent and immunosuppressed mice, together with non-infected mice as control. CY or HCA immunosuppressive drugs were used to induce neutropenia and phagocytic dysfunction in mice, respectively. Immunocompetent mice infected with *A. fumigatus* demonstrated a large and rapid influx of macrophages into the lung within 4 h of infection ([Figure 3](#fig3){ref-type="fig"}A, second row and 3B). Inflammation was quickly resolved, with a return to near-baseline macrophage levels by 24 h ([Figure 3](#fig3){ref-type="fig"}B). By contrast, both forms of immunosuppression sharply reduced the immediate innate response to infection, with poor influx at 4 h ([Figure 3](#fig3){ref-type="fig"}A, third and fourth row and 3B). In both cases, this defect in the immediate response corrected with a more chronic inflammatory signal, with large macrophage influx out to at least 3 days post infection ([Figure 3](#fig3){ref-type="fig"}B), consistent with a model where the defective immediate response allowed infection to become invasive and chronic. We observed and quantified a higher fluorine MRI signal intensity in the HCA mice as compared with the CY mice groups at the site of inflammation post pulmonary infection. No detectable fluorine signal was observed from the non-infected immunocompetent mice (N-IC).Figure 3^19^F MRI Identifies the Differential Local Immune Response to Infection by *A. fumigatus* in Immunocompromised Murine Hosts(A) ^19^F MR images (fluorine signal was superimposed on anatomical ^1^H MR images) were obtained from HCA, CY, and infected-immunocompetent (I-IC) mice as well as non-infected control mice (N-IC) on day 0 (4 h post infection). All mice received systemic injection of ZPFCE-NPs on day 0 (4 h post infection) and day 1. All infected mice were imaged daily (^1^H and ^19^F MRI). The non-infected immunocompetent (N-IC) group was followed up on day 0 and day 3. Labels for different organs (image top left) include H, heart; L, lungs; and R, reference containing 30 mM ZPFCE-NP. Scale bar is 2.6 cm.(B) Quantification of the ^19^F MR signal from the lung region was performed for all groups by comparing the signal intensity of the lung region with a reference (R in (A) top left image) containing 30 mM ZPFCE-NPs. Data shown as mean ± SEM (\*p \< 0.05).(C) ^19^F MRI signal was observed from the lymph node region only for mice from the HCA group on day 1. Mean ^19^F MR signal intensity was quantified with respect to the 30 mM reference placed next to each animal. ^19^F MRI signal in lymph nodes is indicated as hot spots overlaid over the anatomical ^1^H MR image (right panel). Data shown as mean ± SEM (~\*~p \< 0.05).

Key differences were also observed between the immunosuppressed groups, with HCA-treated mice but not CY-treated mice, resulting in a transient flux of macrophages into the cervical lymph nodes on day 1 post infection ([Figure 3](#fig3){ref-type="fig"}C). This indicates that HCA allows macrophage mobilization but diverts recruitment into the draining lymph node rather than into the tissue.

To monitor progression of infection, we applied a cumulative scoring of ^1^H MR images based on the lung signal intensity in all murine groups. This shows the pathophysiological changes occurring over time following infection from day of infection (day 0) until day 3 ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We have observed high signal intensities in the CY group where infection was more profound compared with the HCA group ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Together, these results both validate ^19^F MRI as an *in vivo* monitoring tool for anti-microbe responses and indicate a critical window of response for the innate immune system against *A. fumigatus* invasive infection.

Distinctive Fungal Burden Depicted by Bioluminescent Imaging and Colony-Forming Units Confirms Infection {#sec2.3}
--------------------------------------------------------------------------------------------------------

To affirm infection and viable pulmonary fungal load with inflammatory processes that we have monitored by ^19^F MRI, we have examined the Fluc^+^ *A. fumigatus* infection 3 days after infection by using *ex vivo* bioluminescent imaging (BLI). After D-luciferin administration in the lungs, CY-treated mice showed higher BLI signal intensity compared with the hydrocortisone-treated mice ([Figure 4](#fig4){ref-type="fig"}A). No detectable bioluminescence signal was observed from the lungs in the two control groups, infected immunocompetent and non-infected mice. Quantification of BLI signal also showed significantly high fungal infection in the CY-treated group compared with the hydrocortisone-treated group and infected-immunocompetent group ([Figure 4](#fig4){ref-type="fig"}B). This indicates strong invasion of fungi in the lungs of the CY group owing to lack of an efficient immune response compared with the HCA group, where the immune response prevents the growth of *A. fumigatus*.Figure 4Visualization and Quantification of Fungal Load Reveals the Impaired Immune Response against *A. fumigatus* Invasion in Immunocompromised Mice(A) *Ex vivo* bioluminescent imaging (BLI) was performed to visualize firefly luciferase (Fluc)-expressing *A. fumigatus* in the lungs 3 days after the infection. After the endpoint ^19^F MRI experiment, animals were sacrificed and D-luciferin was administered into the excised lungs of murine groups of mice. Lungs were imaged immediately after D-luciferin administration. The scale bar represents BLI signal intensity in photons flux/second. The color-coded BLI images are overlaid onto the photographic images of lungs. Intensity thresholds for all BLI images were kept the same.(B) BLI signal intensity from all murine groups was measured as total flux after assigning identical regions of interest on the BLI images of lungs.(C) Lungs were isolated 3 days after infection from all mice groups. Colony-forming units (CFUs) were manually counted from lung homogenates 24 h after incubation at 37°C. No fungi were observed in the two control groups (N-IC and I-IC). Data are represented as mean ± SEM (\*p \< 0.05, \*\*\*\*p \< 0.0001). HCA *n* = 5, CY *n* = 6, I-IC *n* = 4, N-IC *n* = 3.

For the quantification of pulmonary fungal load, we performed colony-forming unit (CFU) counting on the cultured lung homogenates from all mice groups. We observed a significant increase in the *A. fumigatus* burden in the lungs of the CY group when compared with the HCA on day 3 ([Figure 4](#fig4){ref-type="fig"}C). In contrast, N-IC and I-IC groups did not show any fungal growth. These results together with ^19^F MRI suggest the early immune activation in infected mice as a critical aspect for the control of potentially invasive *A. fumigatus* progression.

Validation of ZPFCE-NP-Labeled Immune Cell Recruitment in the Lungs and Lymph Nodes by Histology and Immunofluorescence Imaging {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------

To validate our imaging results, we performed periodic acid-Schiff (PAS) staining and immunofluorescence after sacrificing the animals 3 days after infection. Similar to ^19^F MRI, we observed high pulmonary inflammation in the lung tissue of the HCA group upon *A. fumigatus* challenge with minimal fungal invasion. In contrast, the CY group, showed as expected fungal growth and hyphal growth formation with invasion in nearby tissues and no visible inflammation ([Figure 5](#fig5){ref-type="fig"}A). The two control N-IC and I-IC mice groups showed normal lung tissue morphology with no fungal infection on day 3, validating the ^19^F MRI findings.Figure 5Histological Imaging Elucidates Diverse Infection and Inflammation Patterns in Immunocompromised Groups(A) Representative light microscopy of PAS-stained images showing histopathology from the PFA fixed lung sections of different mice groups on day 3 post infection. Excessive immune cell infiltration near the bronchi and bronchiole upon pulmonary *A. fumigatus* infection in HCA mice showing profound inflammation-induced tissue destruction. Mild fungal infection observed in HCA mice (black arrows, HCA magnified image). Fungal dissemination shown in the CY mice resulted in compression of lung tissue with massive hyphal growth (magnified CY image). Scale bar is 200 μm for the first and second rows and 50 μm for magnified images (third row).(B) Immunofluorescence microscopy performed on fresh-frozen lung tissues showing the ZPFCE-NP-labeled macrophages (anti CD11b) and dendritic cells (anti CD11c) recruited to the bronchioles (white arrows) in the lungs of HCA and CY mice. Granulocytes (anti-GR1) were also found to be accumulated (white arrows) in high numbers in the HCA group compared with other groups. Scale bar is 100 μm, and staining represented as Blue = DAPI, Red = ZPFCE-NPs.

Immunofluorescence images also showed the presence of stringent inflammation resulting in higher influx of ZPFCE-NP-labeled macrophages and dendritic cells in the lungs of the HCA group in contrast to the CY group ([Figure 5](#fig5){ref-type="fig"}B, third and fourth row). Additionally, elevated recruitment of granulocytes was observed near the airways of the HCA group compared with other groups. The N-IC and I-IC groups showed no visible inflammation or infection similar to ^19^F MRI ([Figure 5](#fig5){ref-type="fig"}B, first and second row). We also noticed differences in white blood cell counts, analyzed individually from the peripheral blood of different groups on day 3, indicating severe inflammation in the HCA group reflected by an increase in the number of neutrophils and lymphocytes in the blood in contrast to the CY group ([Figure S3](#mmc1){ref-type="supplementary-material"}). The non-infected model showed similar levels of neutrophils and lymphocytes as the I-IC model where immune cells were in the normal range. Notably, the cervical lymph nodes of the HCA group showed high ZPFCE-NPs accumulation ([Figure S4](#mmc1){ref-type="supplementary-material"}). ZPFCE-NPs were also visualized in the OCT (optimum cutting temperature)-embedded lungs on day 3 by *ex vivo* fluorescence imaging illustrating high fluorescent signal observed both in the lungs and cervical lymph nodes, only in the HCA group ([Figure S5](#mmc1){ref-type="supplementary-material"}). Briefly, these results strongly support the ^19^F MRI findings, demonstrating the feasibility of our established methodology for non-invasive monitoring of infection.

Discussion {#sec3}
==========

With the increased number of immunocompromised patients, it becomes more important to closely monitor those patients, diagnose, and follow up IPA. Among the profound number of clinical IPA cases, 90% are caused by *A. fumigatus* ([@bib28], [@bib30]). For a better understanding of aspergillosis and for testing of novel antifungal compounds, preclinical animal models are essential. Although methods for monitoring the dynamics of the immune cells upon *A. fumigatus* infection have been developed recently ([@bib21]), these studies were not able to assess the interaction with the host\'s immune system longitudinally *in vivo*. Here, we have developed an approach that allows the non-invasive, dynamic monitoring of both inflammatory processes and the infection in three different animal models of IPA.

Several cell-labeling approaches have been established to non-invasively visualize the mechanisms of immune reactions involved in various diseases by tracking the loci of inflammatory immune cells using ^19^F MRI ([@bib10], [@bib13], [@bib17], [@bib47]). In this study, we focused on the quantification and localization of inflammation in IPA murine models of immune impairments induced by clinically used immunosuppressive drugs ([@bib3], [@bib46], [@bib54]). PFCs have been used and tested as blood substitutes and thus proven to be safe in humans ([@bib19], [@bib37]). Here, we synthesized ZPFCE-NPs and studied their potential for the labeling of phagocytic immune cells. It has been shown that labeling with PFCE particles of different sizes could potentially modulate the immune function of dendritic cells ([@bib51]). In this study, we showed the biological compatibility of ZPFCE-NPs for *in vivo* studies, where labeled macrophages retained their antigen processing and T cell activation capacity. Compared with most other PFCs, ZPFCE-NPs have a reduced size of ∼280 nm ([@bib9]).In our *in vivo* study, we have used ^19^F MRI to quantify inflammation non-invasively and longitudinally after systemic injections of ZPFCE-NPs. The ^19^F MRI signal detected in inflamed areas corresponds to the infiltration of labeled phagocytic cells in the region of interest ([@bib13], [@bib49]). We observed high ^19^F MRI signal intensities in the lungs of the infected immunocompetent (I-IC) mice already 4 h after the fungal infection, which was completely cleared after 24 h, confirming the expected eradication of *A. fumigatus* conidia by the immune system. In the hydrocortisone (HCA)-treated mice, the exacerbated intrusive recruitment of immune cells resulted in the labeling of not only tissue-resident macrophages but also dendritic cells ([@bib48]). Inflammation was found to be less pronounced in the CY-treated mice, with increased fungal invasion in the lungs. We did not observe any detectable fluorine signal in the lungs from the non-infected immunocompetent (N-IC) mice that have received ZPFCE-NPs, indicating absence of any inflammation in the lungs. Only in HCA mice, elevated accumulation of ZPFCE-NPs was observed in the nearby cervical lymph nodes to 3 days after infection as shown in the ^19^F MR images.

In addition to ^19^F MRI, *in vivo* ^1^H MRI in these mouse models was able to document the lesion development occurring in the lungs upon fungal conidia challenge. As shown by our quantitative image analysis, we observed high lung lesion formation in CY mice two and three days after infection, which is consistent with profound fungal hyphal growth and invasion in lungs as reported before ([@bib33]). ^1^H MRI indicated only weak lesion formation in the infected HCA-treated and I-IC groups. These results endorse the fact that the administration of CY as a frequently used immunosuppressive drug can lead to lethal IPA with mild initial inflammation in the lungs as indicated by ^19^F MRI. On the contrary, hydrocortisone-based immunosuppression leads to less lesion formation by *A. fumigatus* but triggers acute inflammation leading to potentially lethal tissue destruction ([@bib21]). The functional immune system of the infected-immunocompetent mice resulted in the rapid initial immune reaction and complete clearance of the fungi as shown in the ^1^H MR images and also confirmed by histology. By using ^19^F MRI, we were able to monitor the intricate dynamic profile of the host-pathogen interaction in pulmonary *A. fumigatus* infection *in vivo.* We documented the differences between immunocompetent hosts and animals treated with two different immunosuppressive compounds. With clinically safe contrast agents like perfluorocarbon (PFC)-based fluorinated nanoparticles, ^19^F MRI not only proved to be a powerful imaging modality for numerous preclinical studies but also showed potential for translation to humans. For immune cell imaging, ^19^F MRI has developed into a robust method for the follow-up of phagocytic cells with less success in the tracking of non-phagocytic cells owing to the sensitivity issues of ^19^F MRI ([@bib38]).

In summary, we demonstrated the potential of ^19^F MRI and perfluorocarbon-based ZPFCE-NPs by successful tracking and quantifying the fluorine signal generated by innate immune cells, macrophages, and dendritic cells in the lungs corresponding to the intensity of local inflammation. By being able to monitor both the infection and immune reaction in live animals over time, it is possible to make treatment decisions rapidly and almost in real time. In the future, this will help in testing transgenic fungal strains, novel antifungal drugs, or new approaches to influence the immune system. Overall, it will provide an emerging ^19^F MRI platform for studying not only basic mechanisms of fungal infections but also advanced immune cell therapies in patients ([@bib1], [@bib2], [@bib12], [@bib15]).

Limitations of the Study {#sec3.1}
------------------------

Although the PFC-based fluorinated nanoparticles provided specific contrast for immune cell imaging in the preclinical aspergillosis models, ^19^F MRI is still limited to applications where large cell numbers accumulate locally. For less severe models of inflammation, the sensitivity of ^19^F MRI needs to be improved by using either contrast agents with higher fluorine load or improved hardware ([@bib23]) and/or image processing approaches ([@bib26]). In addition, *in vivo* cell labeling was restricted to phagocytic cells like macrophages. Animal models used in this study were already described by invasive methods. In the future, a comparative experiment using a PRR knockout mouse strain instilled with a transgenic fungus lacking a key PAMP (e.g., melanin or galactosaminoglycan) can be used as a suitable model to study the immune response in differently modulated transgenic animals.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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